FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today announced it has received a significant signed purchase contract including a purchase order valued at approximately $500,000 from one of the world's largest and most respected biopharmaceutical companies. This order is for the complete integration of TOMI's SteraMist Integrated Systems (SIS) platform into critical manufa ...

FREDERICK, Md., Dec. 15, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, is calling upon cruise lines to improve decontamination and adopt hospital-grade technology like SteraMist as a compromise-free standard for advanced maritime decontamination. “The question should no longer be if cruise lines can prevent health outbreaks, but how often and how comprehensively they are utilizing hospital-grade disinfecti ...

Summary of TOMI Environmental Solutions Conference Call Company Overview - **Company Name**: TOMI Environmental Solutions - **Ticker**: TOMZ - **Industry**: Disinfection and Decontamination - **Product**: SteraMist, an eco-friendly disinfection solution developed from DARPA technology Core Points and Arguments - **Product Efficacy**: SteraMist utilizes a low-percentage hydrogen peroxide (7.8%) converted through a cold plasma arc to create hydroxyl radicals that effectively neutralize pathogens, including spores and viruses, without leaving any residue [2][3][4] - **Market Opportunity**: The global market for disinfection is vast, spanning multiple industries including biotech, food and beverages, commercial services, and healthcare, with significant growth expected [4][16] - **Competitive Landscape**: Major competitors include STERIS and Bioquell, with TOMI positioned to outperform due to its unique technology and faster, more effective disinfection capabilities [5][10] - **Client Base**: Notable clients include Pfizer, Merck, NASA, and various government agencies, which validate the product's effectiveness and reliability [3][19] - **Regulatory Compliance**: The company adheres to stringent regulations, including FDA and EMA compliance, which enhances its credibility in the market [16][20] Financial Performance - **Revenue Growth**: Revenues increased by 38% over pre-COVID levels, with a 40% growth in the first half of 2025 compared to the same period in 2024 [21][14] - **Margins**: The company maintains gross margins of approximately 60%-62% [10][23] - **Recurring Revenue Model**: The business model is based on a "razor and blade" approach, where equipment sales drive recurring revenue from consumables [10][25] Market Segments - **Biotechnology and Life Sciences**: This segment is the largest revenue generator, including applications in pharmaceuticals and clean rooms [5][6] - **Food Safety**: Growing segment with increasing demand for sanitation solutions due to stricter regulations and food safety concerns [18][19] - **Healthcare**: Significant potential for growth, especially in hospitals, where SteraMist has demonstrated effectiveness in reducing infection rates [20][21] Future Outlook - **Market Expansion**: The company is focused on expanding its sales force and enhancing training programs to penetrate more healthcare facilities and other verticals [22][23] - **Technological Advancements**: Ongoing development of custom integration units and partnerships with laboratory equipment manufacturers to embed SteraMist technology [10][11] - **Regulatory Tailwinds**: Increased focus on biosecurity and infection control post-COVID is expected to drive demand for SteraMist solutions [16][24] Additional Insights - **Case Studies**: Successful case studies, such as the reduction of C. diff cases in hospitals, provide strong evidence of product effectiveness [20] - **Environmental Impact**: SteraMist's eco-friendly profile, with water and humidity as the only byproducts, positions it favorably against traditional disinfection methods [29][30] - **Global Health Concerns**: The company is prepared to address potential outbreaks and pandemics, leveraging its technology to provide effective solutions [24] This summary encapsulates the key points discussed during the TOMI Environmental Solutions conference call, highlighting the company's strengths, market opportunities, and future growth potential.

FREDERICK, Md., Dec. 04, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, announced today that it will be presenting at the Sidoti Year End Investor Conference being held virtually on December 10-11, 2025. Dr. Halden Shane, CEO and Chairman of the Board, and David Vanston, Chief Financial Officer, wil ...

Core Insights - TOMI Environmental Solutions, Inc. has made significant progress in its custom integration pipeline, valued at approximately $3 million, indicating strong momentum in the life sciences sector [1][6] - The company is strategically positioned as a turnkey solution provider in regulated industries, focusing on disinfection and decontamination solutions that are highly valued [2][7] Project Pipeline and Business Development - TOMI currently has ten active projects across its SteraMist Integrated System (SIS) and Custom Engineered System (CES) platforms, catering to both new and existing customers [1][5] - Several projects are expected to be completed by the end of the year, with additional initiatives in the procurement and planning stages, suggesting sustained business development into 2026 [5][10] Strategic Partnerships - The company's success is attributed to strategic partnerships with major enclosure manufacturers such as ESCO Micro Pte. Ltd., Steelco S.p.A., and others, which enhance TOMI's role as a bridge between advanced technology and practical application [3][4] - These partnerships facilitate the seamless integration of TOMI's iHP technology into existing systems, addressing market demand for comprehensive decontamination solutions [4][9] Market Positioning - TOMI focuses on serving the life science and medical device sectors, where contamination control is critical for product quality and patient safety [7][12] - The SIS and CES platforms offer customization capabilities to meet unique operational requirements, positioning TOMI as a strategic partner rather than just an equipment supplier [8][12] Long-term Growth Strategy - The company's emphasis on high-value partnerships in specialized sectors reflects a business model aimed at sustainable expansion rather than rapid volume growth [12] - By leveraging established manufacturer relationships, TOMI enhances its market presence and ensures customers receive integrated solutions with comprehensive support [9][12]

Core Viewpoint - TOMI Environmental Solutions, Inc. has filed a $50 million universal shelf registration statement with the SEC to enhance its financial flexibility for operational growth and strategic initiatives [1][2]. Financial Strategy - The registration statement will allow TOMI to offer and sell securities as needed, providing the company with the ability to efficiently access capital [2]. - TOMI has entered into a strategic advisory and placement arrangement with Bancroft Capital and established an equity line of credit (ELOC) facility with Hudson Global Ventures, allowing the sale of up to $20 million of common stock over a 24-month period [3]. Operational Performance - The CEO of TOMI highlighted strong sequential revenue growth and improved gross margins in Q3, indicating expanding customer adoption of the SteraMist® technology [4]. - The financing from the ELOC is intended to accelerate investments in innovation, manufacturing efficiency, and global distribution [4]. Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination through its Binary Ionization Technology® (BIT™) platform, which utilizes a low percentage of Hydrogen Peroxide to create a germ-killing aerosol [5]. - The company's products are designed for a wide range of commercial structures, including hospitals, cruise ships, schools, and military facilities [6].

Core Insights - TOMI Environmental Solutions, Inc. reported a quarterly loss of $0.02 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.01, marking a 100% earnings surprise [1] - The company generated revenues of $2.12 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 22.77% and down from $2.54 million year-over-year [2] - The stock has underperformed, losing approximately 22.9% since the beginning of the year, while the S&P 500 has gained 14.6% [3] Financial Performance - Over the last four quarters, TOMI Environmental Solutions has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $3.63 million, and for the current fiscal year, it is -$0.10 on revenues of $8.98 million [7] Industry Outlook - The Waste Removal Services industry, to which TOMI belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact TOMI's stock performance [5] Future Expectations - The company's earnings outlook will be crucial for assessing future stock performance, particularly in light of management's commentary during the earnings call [4] - The estimate revisions trend for TOMI was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market [6]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in iHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year-over-year in life sciences and food safety [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIT solution sales increased by 21% year-to-date, contributing to the overall revenue growth [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide positions the company to serve not only life sciences and healthcare but also agriculture, food processing, and environmental biosafety [7][23] - The active pipeline surpassed $15 million, encompassing both domestic and international customers across various industries [6] Company Strategy and Development Direction - The company aims to enhance customer engagement and expand its recurring revenue streams through personalized outreach and targeted marketing campaigns [8] - Focus on biosecurity advancements and scaling automation integrations for high-efficacy environments is prioritized for 2026 [8][9] - The company is investing in innovation and customer success to capture opportunities in clean tech and biosecurity [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's recovery and reaffirmed the soundness of its strategy, with steady improvement expected financially, operationally, and strategically [25][26] - The company is well-positioned for a successful fourth quarter with momentum carrying into 2026, supported by a recent equity purchase agreement to access capital [26][27] Other Important Information - The company celebrated a significant addition to its customer roster with Bausch + Lomb, which adopted mobile handheld surface units and committed to BIT Solution orders for 2026 [19][20] - The company is actively pursuing the cannabis market and has opened doors to promising new partnership discussions [22] Q&A Session Summary Question: What are your sales and marketing efforts towards the FDA approval for hydrogen peroxide usage? - Management indicated that the food industry could be a key marketing vertical, and they are excited about the approval as it positions their technology favorably [29] Question: Should we expect operating expenses and gross margins to continue improving? - Management expects operating expenses to increase but remain positive in relation to revenue, with gross margins expected to hold steady [30][31] Question: What kind of sales effort is in place for international markets like Morocco? - The company has distributors in various countries and is working with global partners to increase demand for SteraMist [34] Question: Do you have visibility on solution sales in the coming quarters? - Management noted that while there was a decrease in solution sales growth in Q3, they expect a rebound by the end of the fourth quarter [35] Question: Any updates on servicing military and defense markets? - Management mentioned ongoing studies with a key site looking to replace formaldehyde, with expectations for significant developments in 2026 [42] Question: Any progress in the use of SteraMist for replacing ethylene oxide in medical sterilization? - Management confirmed ongoing discussions and prioritization of partnerships in device manufacturing for this purpose [51]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in IHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year over year in the life sciences and food safety areas [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIP solution sales increased by 21% year to date, contributing to the overall revenue growth [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide as a safe disinfectant opens new markets, particularly in food processing and agriculture [7][23] - The company is seeing strong interest from emerging sectors, with an active pipeline surpassing $15 million [6][7] Company Strategy and Development Direction - The company aims to grow sales of mobile capital equipment, IHP corporate service, and custom integration platforms alongside its core BIP solution business model [5][8] - There is a focus on biosecurity advancements and scaling automation integrations for high-efficacy environments, addressing global challenges [8][9] Management's Comments on Operating Environment and Future Outlook - Management believes the third quarter marked a decisive turning point, with a 95% sequential revenue increase driven by expanding recurring revenue streams [4][5] - The company is optimistic about the future, with a strong sales backlog and a sales strategy beginning to deliver promising results [25][26] Other Important Information - The company entered into an equity purchase agreement with Hudson Global Ventures, allowing it to sell up to $20 million in common stock over a 24-month period [26] - The SteraMist IHP technology was named the Disinfection and Decontamination Products Company of the Year 2025 [7] Q&A Session Summary Question: What are the sales and marketing efforts towards the FDA approval for hydrogen peroxide usage? - Management sees the food industry as a key marketing vertical and is excited about the approval, which is expected to be a game changer [29] Question: Should operating expenses and gross margins continue to improve? - Management expects operating expenses to increase but believes they will be positive in relation to revenue, with gross margins remaining stable [30][31] Question: What kind of sales effort is in place for international markets like Morocco? - The company has different distributors in various countries and is working with global partners to increase demand for SteraMist [34] Question: What visibility is there on solution sales in the coming quarters? - Management anticipates that solution sales will increase as more technology is deployed, with a key focus on driving growth in BIP solution sales [35] Question: Any updates on servicing military and defense markets? - The company is working with a key site looking to replace formaldehyde and expects significant developments in 2026 [42] Question: Any progress in the use of SteraMist for replacing ethylene oxide in medical instrument sterilization? - The company is prioritizing partnerships in device manufacturing to streamline IHP into decontamination processes [51]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in IHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year over year in the life sciences and food safety areas [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIP solution sales increased by 21% year to date, indicating a positive trend in this segment [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide as a safe disinfectant opens new markets, particularly in food safety, agriculture, and environmental biosafety [7][23] - The company is seeing strong interest from emerging sectors, with an active pipeline surpassing $15 million [6] Company Strategy and Development Direction - The company aims to grow sales of mobile capital equipment, IHP corporate service, and custom integration platforms alongside its core BIP solution business model [5] - There is a focus on biosecurity advancements and scaling automation integrations for high-efficacy environments, addressing global challenges [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's recovery and strategic execution, highlighting steady improvement financially, operationally, and strategically [25] - The company is well-positioned for a successful fourth quarter with momentum carrying into 2026, supported by a recent equity purchase agreement to access capital [26] Other Important Information - The company has been recognized as the Disinfection and Decontamination Products Company of the Year 2025, validating its solutions and positioning [7] - The company is expanding its training programs and customer engagement strategies to enhance market penetration [8] Q&A Session Summary Question: What are the sales and marketing efforts towards the FDA approval for hydrogen peroxide? - Management indicated that the food industry could be a key marketing vertical, and they are excited about the approval as it positions their technology favorably [30] Question: Should we expect operating expenses and gross margins to continue improving? - Management expects operating expenses to increase but remain positive in relation to revenue, with gross margins holding steady [31][32] Question: What kind of sales effort is in place for international markets like Morocco? - The company has distributors in various countries focused on increasing demand for SteraMist [36] Question: Do you have visibility on solution sales in the coming quarters? - Management noted that while they had a 40% increase in solution sales earlier in the year, they expect recurring sales to rise again by the end of Q4 [37] Question: Any updates on servicing military and defense markets? - Management mentioned ongoing studies with a key site looking to replace formaldehyde, expecting significant developments in 2026 [43] Question: Progress on CAR T-cell disinfection business? - No updates were provided on this front [45] Question: Expectations on the rollout by major service provider companies in healthcare mold remediation? - Management expressed optimism about rapid rollouts due to strong initial assessments and training support [46] Question: Plans to penetrate the disinfection market for data centers? - Management acknowledged the interest in data centers and the need for disinfection, indicating plans to expand the sales team for this vertical [49] Question: How is the company increasing awareness for the food industry post-FDA ruling? - The company is focusing on social media and reaching out to existing contacts in the food safety sector [51] Question: Any progress in using SteraMist for replacing ethylene oxide in medical sterilization? - Management confirmed ongoing discussions and prioritization of partnerships in this area [54]